News
Barchart on MSN5d
Regeneron Pharmaceuticals Earnings Preview: What to Expect
Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,030.00. The company’s shares closed yesterday at $686.33.
Jefferies analyst Akash Tewari maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,200.00. The company’s shares opened today at $710.20.
Regeneron Pharmaceuticals Inc. Annual stock financials by MarketWatch. View the latest REGN financial statements, income statements and financial ratios.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback